# HIV-1 transcription dominates over host gene activity at the HIV-1 integration site

**Authors:** Samuel Weissman, Yang-Hui J. Yeh, Miriam Viazmenski, Rachel Kim, Jack A. Collora, Savannah Steinhauser, Ya-Chi Ho

PMC · DOI: 10.1128/mbio.02755-25 · mBio · 2025-11-24

## TL;DR

This study shows that HIV-1 transcription is not influenced by nearby host gene activity and instead dominates at the integration site, contributing to persistent immune activation even with ART.

## Contribution

The study reveals that HIV-1 transcription is not passively regulated by host gene activity but actively dominates at the integration site.

## Key findings

- Host gene activation or inhibition does not affect HIV-1 transcription levels.
- HIV-1 drives aberrant host RNA transcription regardless of integration orientation or location.
- Silencing the HIV-1 promoter is necessary to prevent HIV-1-induced immune activation.

## Abstract

Despite effective antiretroviral therapy (ART), HIV-1 persists as an integrated DNA provirus in the genome of infected cells. Host cells can regulate HIV-1 transcription at the HIV-1 integration site dependent on the location (actively transcribed genes vs repressive chromatin) and the orientation (in the same vs opposite orientation of the host gene transcription) of HIV-1 integration. Presumably, HIV-1 follows the host gene transcriptional activity at the HIV-1 integration site. We interrogated HIV-1-host gene transcriptional interactions at the HIV-1 integration site using CRISPR-mediated activation and inhibition of the host genes (in which HIV-1 was integrated) in seven HIV-1-infected Jurkat T cell clones with known HIV-1 integration sites in the introns of actively transcribed genes and a non-genic region. Using ATAC-seq and strand-specific RNA-seq to examine chromatin accessibility and RNA transcription levels, we found that host gene activation did not increase HIV-1 transcription, while host gene inhibition did not decrease HIV-1 transcription. HIV-1 drove high levels of aberrant host RNA transcription regardless of the HIV-1 integration orientation. HIV-1-driven aberrant host RNA transcription was inhibited by CRISPR-mediated HIV-1 inhibition but not by CRISPR-mediated host gene activation or inhibition. When HIV-1 was integrated into a non-genic region, HIV-1 increased host chromatin accessibility and drove high levels of aberrant host RNA transcription. Overall, HIV-1 LTR promoter-driven transcriptional activity dominated over the host promoter activity. HIV-1 transcription does not passively follow host gene activity. Our results highlight that despite effective ART, silencing HIV-1 promoter is required to inhibit HIV-1-driven aberrant host gene expression and chronic immune activation.

HIV-1 persists as an integrated provirus in infected cells. Antiretroviral therapy (ART) does not inhibit HIV-1 promoter activity. Therefore, despite effective ART, HIV-1 promoter continues to drive HIV-1 antigen expression and induce chronic immune activation. HIV-1 eradication relies on either effective HIV-1 latency reversal (the shock-and-kill strategy) or permanent HIV-1 silencing (the block-and-lock strategy). Therefore, understanding the transcriptional regulation of HIV-1 expression is key to HIV cure. Presumably, HIV-1 transcription passively follows host gene activity at the HIV-1 integration site. Using a CRISPR-mediated host gene activation and inhibition, we found that host gene activation does not increase HIV-1 transcription, while host gene repression does not inhibit HIV-1 transcription. HIV-1 drives aberrant host RNA expression even when HIV-1 is integrated into a non-genic region. Overall, HIV-1 dominates over host gene activity at the HIV-1 integration site. Despite ART, additional strategies silencing HIV-1 promoter activity are required to halt HIV-1-induced chronic immune activation.

## Linked entities

- **Genes:** ltr (loiterer) [NCBI Gene 10216629]
- **Chemicals:** doxorubicin (PubChem CID 31703)

## Full-text entities

- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676]
- **Cell lines:** Jurkat T — Homo sapiens (Human), Childhood T acute lymphoblastic leukemia, Cancer cell line (CVCL_0065)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12802265/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12802265/full.md

## References

70 references — full list in the complete paper: https://tomesphere.com/paper/PMC12802265/full.md

---
Source: https://tomesphere.com/paper/PMC12802265